Condition
Relapsed Diffuse Large B Cell Lymphoma
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT04792489Phase 2Recruiting
DALY II USA/ MB-CART2019.1 for DLBCL
NCT06458439Phase 2Recruiting
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Showing all 2 trials